Tiffany Shih, MS, PhD
Senior Research Economist
Dr. Shih’s expertise includes the application of microeconomic theory and econometric methods to address issues in the healthcare field. Her work has used a variety of quantitative methods to estimate the value of medical innovation. She specializes in causal inference to assess the impacts of healthcare policies or real-world outcomes from therapeutic use. An example of her recent work applies economic theory and empirical estimation to quantify the value of therapies to healthy, risk-averse individuals who fear the risk of becoming ill. Prior to joining PHE, Dr. Shih taught in the economics department at UCLA and in the Fuqua School of Business at Duke University.
PhD, Agricultural and Resource Economics, University of California, Berkeley
MS, Energy and Resources, University of California, Berkeley
BS, Biology, Stanford University
ASSOCIATED CASE STUDIES
- Cope S, et al. Expert elicitation of long-term survival for pediatric acute lymphoblastic leukemia patients receiving CTL019 in Eliana Phase II study. Blood. 2017.
- Fuhr JP, et al. Product naming, pricing, and market uptake of biosimilars. GaBI J. 2015.
- Romley J, et al. Product safety spillovers and market viability for biologic drugs. Int J Health Econ Manag. 2016.
- Shih T, et al. Reconsidering the economic value of multiple sclerosis therapies. Am J Manag Care. 2016.
- Shih T. The rising burden of preeclampsia in the United States impacts both maternal and child health. Am J Perinatol. 2016.